Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclacel Pharmaceuticals, Inc.
A randomized Phase II study of an experimental anti-cancer drug called seliciclib with objectives of evaluating safety and efficacy in patients with non-small cell lung cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
Must have measurable disease according to RECIST
Eastern Cooperative Oncology Group performance status 0-1
Adequate bone marrow, hepatic and renal function
Ability to swallow capsules
At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities
At least 3 weeks from major surgery
You may not be if
Non-small cell cancer histology contains a component of small cell lung cancer
Previously untreated CNS metastasis or progressive CNS metastasis
Prior treatment with a CDK inhibitor
Currently receiving radiotherapy, biological therapy, or any other investigational therapy
Uncontrolled intercurrent illness
Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer
